Ovarian Cancer CRO & Clinical Development Services

Accelerating Ovarian Cancer research through expert clinical trial management. We support studies from early detection biomarkers to late-stage therapeutic interventions.
Our oncology teams possess deep expertise in gynecologic cancers. We manage complex ovarian cancer trials involving PARP inhibitors, immunotherapies, and surgical interventions. With a focus on rapid startup and site engagement, we help you reach your clinical milestones faster.

Trusted Partner for Complex Oncology Studies

We manage complex designs including imaging studies, combination therapies, and basket/cohort trials, with full global operational support and patient-centric strategies that improve retention and engagement.

8+
ovarian cancer studies
20+
gynecological cancer studies
500+
oncology studies
32k+
oncology patients across 3800 sites

Supporting Ovarian Cancer Trials

Our structured, proactive approach ensures your trial stays on track, even in highly complex clinical environments.

Operational Highlights:

  • Expertise across Phase I–IV, including cohort-based and adaptive trial designs
  • Experience with complex imaging protocols and site coordination
  • Integrated Oncology Executive Oversight team throughout the project lifecycle
  • Proven success in recruiting difficult-to-reach populations and supporting site performance

A Journey of Overcoming Obstacles and Maximizing Patient Enrollment

Discover how Ergomed Clinical Research helped a biopharmaceutical company overcome enrollment challenges in a Phase II ovarian cancer trial. With our Study Physician Service, we accelerated recruitment and exceeded targets, ensuring the study’s success.

Transforming First-in-Human Oncology Trials: A Strategic Guide

Ergomed empowers biopharma sponsors to design and deliver first-in-human oncology trials with confidence—combining regulatory expertise, patient-centric strategies, and operational excellence to accelerate early-phase development and reduce risk.

Precision, Partnership, and Patient Focus

Ergomed combines scientific insight, global infrastructure, and patient-first execution to deliver ovarian cancer studies with precision and care. Our experience spans complex imaging protocols, multidisciplinary coordination, and the management of highly specialized compounds—ensuring trials remain on track from first patient in to study close.

Experience With Ovarian Cancer Populations

With extensive experience in ovarian cancer studies, we ensure clear communication of patient eligibility, scheduling, and site requirements to safeguard timely enrollment and protocol adherence.

Close and Effective Logistics Management

From managing radioactive compound delivery to coordinating complex scanning schedules, Ergomed’s site managers oversee every step of the patient journey. This ensures seamless execution across multiple sites and prevents costly delays or data loss.

Ensuring Effective Patient Support

We recognize the unique challenges of imaging studies and work closely with oncologists, imaging teams, and patients to provide clear information and support. By partnering with sites, we help motivate and prepare patients from consent through study completion.

Ready to Launch Your Ovarian Cancer Study?

Partner with a CRO that brings together deep oncology expertise, scientific insight, and global infrastructure to accelerate your ovarian cancer program. At Ergomed, we go beyond trial execution—we design strategies that anticipate regulatory challenges, optimize patient recruitment, and support sites with tailored solutions.

Ovarian Cancer Trials, Ergo, Global Precision.